Abstract
Investigation of the effects of various antiangiogenic agents in the therapy of solid tumors has been a dominant theme in oncology for the past decade. Hepatocellular carcinoma has joined the short list of tumor types for which single-agent antiangiogenic therapy has shown clear clinical benefit. Here we discuss the findings of a multicenter, phase III trial by Llovet et al., which compared overall survival, time to symptomatic progression, and time to radiologic progression in 602 patients with hepatocellular carcinoma who received either sorafenib (n= 299) or placebo (n = 303). This study showed that patients treated with sorafenib had approximately 3 months longer overall survival and time to radiologic progression compared with patients who received placebo. For optimal clinical application, elucidation of the tumor-specific and patient-specific factors that identify the subpopulation of patients with hepatocellular carcinoma who will derive the greatest benefit from antiangiogenic therapies such as sorafenib is of critical importance.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Liu L et al. (2006) Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66: 11851–11858
Schwartz JD et al. (2006) Bevacizumab in unresectable hepatocellular carcinoma (HCC) for patients without metastasis and without invasion of the portal vein [abstract]. J Clin Oncol 24 (Suppl): S213
Zhu AX et al. (2006) Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 24: 1898–1903
Sun W et al. (2007) Combination of capecitabine, oxaliplatin and bevacizumab in treatment of advanced hepatoce llular carcinoma: a phase II study [abstract]. J Clin Oncol 25: (Suppl): S240
Abou-Alfa GK et al. (2006) Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24: 4293–4300
Llovet JM et al. (2008) Sorafenib in advanced hepatocelluar carcinoma. N Engl J Med 359: 378–390
Cheng A et al. (2008) Randomized phase III trial of sorafenib versus placebo in Asian patients with advanced hepatocellular carcinoma [abstract]. J Clin Oncol 26: 4509
Abou-Alfa GK et al. (2008) Final results from a phase II, randomized, double-blind study of sorafenib plus doxorubicin versus placebo plus doxorubicin in patients with advanced hepatocellular carcinoma [abstract #128] 2008. Gastrointestinal Cancers Symposium: 2008 January 24–27; Orlando, FL.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
KT Flaherty has served as a consultant for Bayer and Onyx Pharmaceuticals. W Sun declared no competing interests.
Rights and permissions
About this article
Cite this article
Flaherty, K., Sun, W. Which questions remain unanswered following the successful development of sorafenib in hepatocellular carcinoma?. Nat Rev Clin Oncol 6, 64–65 (2009). https://doi.org/10.1038/ncponc1299
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncponc1299